Transcranial magnetic stimulation (TMS) is a procedure in which magnetic fields are used to stimulate nerve cells in the brain. With groundbreaking studies breaking new ground in the field of mental health, Deep TMS is very promising to receive approval statuses for additional mental health conditions around the world. After this, the patient underwent EMTR treatment for OCD using the FDA approved protocol for OCD with a double-cone coil (Cool D-B80 coil). The system uses transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation, to stimulate areas of the brain that are underactive in depression.
Therefore, the second episode of seizures appears to be unrelated to RTMS therapy and possibly related to this change in medication. This is different from the other OCD protocols described in the literature, where standard TMS coils are used to stimulate SMA or DLPFC with a low-frequency RTM protocol. Deep EMT (EMT) sends electromagnetic waves deeper than other types of therapy, about 4 centimeters into the brain. It is also important to understand that TMS is not the same thing as electroconvulsive therapy or ECT.
Never disregard professional medical advice or delay seeking it because of something you have read on the CTMSS website. This seizure induction may be the first seizure reported using the recently FDA-approved protocol for OCD targeting DMPFC with a double-cone TMS coil. Deep TMS has received the European CE mark as a sign of its proven ability to relieve the symptoms of a wide range of mental health conditions. Thase says that during this time, her team starts patients on a new antidepressant and weans them from EMT treatment.
A new episode of seizures occurred 10 days after your last EMT session with this new reduced intensity and the above-mentioned changes in your medication. In this case report, we present a patient who experienced a seizure while receiving HF-RTM to DMPFC using a double-cone EMT coil to treat her OCD symptoms. The FDA has awarded the NeuroStar Advanced Therapy System the innovative device designation for the treatment of bipolar depression, according to a press release by Neuronetics Inc. The contents of the TMS Clínicas Society (CTMSS) website, such as text, graphics, images and other materials created by CTMSS or obtained from CTMSS licensors and other materials contained on the CTMSS site (collectively, “Content”) are for informational purposes only.
